FundedIQ
Health Care

Elea

www.elea.health Hamburg, Germany 11-50 employees
Total raised
$4.4M
Rounds
1
Latest
Seed
Mar 2025

Elea is a Health Care company based in Hamburg, Germany.

Elea has raised $4.4M across 1 round. Its most recent round was a Seed of $4.4M in Mar 2025. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Mar 12, 2025
Seed
$4.4M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Elea is featured in

Similar companies

Arab Therapy

Arab Therapy functions as a startup that focuses on mental health.

Seed
Prosoma

Prosoma is a medical company creating digital therapeutics products for cancer patients. We develop a portfolio of digital therapeutics medical software products that cover the entirety of behavioural treatment needs of cancer patients. Our clinically validated platform is set to be prescribed by doctors and therapists in Germany, and it will be reimbursed by the local healthcare system in 2022. We aim to become #1 global digital therapeutics solution for oncology and we have a pathway to get there. Prosoma’s “Software as a Medical Device” platform is a set of stand-alone apps tailored to the different stages of the patient’s journey, which includes: symptoms and treatment support, psycho-social support, and behavioural support. All of these pathways are clinically validated and accessible at any time and anywhere the patient needs it. Our medical self-care applications are designed to deliver therapeutic methods personalised to each patient based on their diagnosis and outcomes. It is the most comprehensive toolset to make patient’s life better. Prosoma is developed by medical experts and patients. We partner with the most renowned organisations for the clinical trials, as well as, large scale commercial partners in the USA and Germany. We are a part of various acceleration programmes such as: Accelerate Cambridge, Incredibles, and the HealthHub at the University of California. Prosoma is being developed and built to meet EU Medical Device Regulations: ISO 13485, ISO 62304, and ISO 27001. We are proud to be funded by a VC fund and Business Angels who support our vision and strategy. In 2020, Prosoma received an NCBiR grant for developing a COVID-19 centred product.

Series A
Mallia Innovations

Mallia Innovations specializes in creating evidence-based hair regeneration solutions that target specific areas, with an emphasis on immunological research, therapeutic effectiveness, and noticeable outcomes.

Seed $6.3M
AlfaDocs

AlfaDocs is the only 100% cloud-based platform for managing client relationships and the entire studio. With AlfaDocs, you can manage your studio activities from any device (a PC, a smartphone, or a tablet), even while you're not in the office, thanks to contemporary cloud technology. Visit our website for more information.

Series A
Idana

Idana is a digital patient intake manager that completely and securely takes care of the intake process. Idana ensures that the information is medically sound, thorough, of high quality, and available at the right time and place. With Idana, caregivers can focus on what they do best - providing patient care.

Series A
HelloBetter

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Series Unknown $6.4M
Caire

Caire aims to incorporate healthcare into daily routines, such as in homes and workplaces.

Pre-Seed $890k
Berlin Heals

Berlin Heals Holding is a company that designs implantable medical devices to treat heart failure.

Series Unknown $7.8M
InflaRx

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI USA.

Series Unknown $30.0M
Avelios Medical

Avelios is a modular clinic platform that digitizes and optimizes all clinic processes in a user-friendly way. The state-of-the-art software supports all staff in their daily work and additionally enables the development and use of innovations such as artificial intelligence, Big Data, telemedicine, patient applications and wearables to fundamentally improve patient care and research.

Series A $31.2M
fabel

The fabel app is created with the specific needs of family caregivers in mind, providing a complete and user-friendly solution to streamline and automatically handle household care duties.

Series Unknown $1.3M
Sedivention

Sedivention develops a break-through, widely applicable, device for interventional obesity therapy. Hunger is transmitted from the stomach to the brain by the gastric trunks of the vagal nerve. Sedivention is developing a cryo-balloon freezing the gastric branches of the vagal nerve from inside the stomach, in a procedure comparable to gastroscopy. The ambulatory intervention takes approximately 20 min. The costs of the intervention are far below costs of bariatric surgery without surgical morbidity and complications. In brief: Sedivention develops the first long-term effective, scalable therapy for obesity: No scars, no pain, no surgical complications, no access barriers at an affordable price. Obesity causes over 400.000 deaths yearly in the US alone and costs of more than 2.0 trillion $US worldwide. According to the WHO obesity Atlas 2022, there will be 1 billion obese persons worldwide in 2030.

Pre-Seed $850k
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.